Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings

Turgut Bozan; Remzi Cevik; İbrahim Batmaz; İbrahim Gündüz; Abdullah Zübeyir Dagli

doi:10.5798/dicletip.1266709

Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings

Öz

Aim: This study investigates serum interleukin(IL)-37 levels in patients with systemic sclerosis (SS) and assesses its relationship with clinical findings. Methods: This study included 35 patients with SS and 30 healthy control subjects. The demographic and clinical characteristics of the patients, such as the presence of Raynaud’s phenomenon, SS subtype, digital ulcers, gastrointestinal and lung involvement, and disease activity, were recorded. The medications used by the patients were recorded, and Serum IL-37 levels were measured using an enzyme-linked immunosorbent assay. The United Kingdom Functional Scoring system was used to evaluate the functional status of the patients, while the Valentini criteria were used to evaluate disease activity. Skin involvement was evaluated based on the modified Rodnan skin score. Results: Although serum IL-37 levels were found to be lower in patients with SS than in the control group, the difference was not statistically significant (p= 0.078). A negative correlation was identified between serum IL-37 levels and C3 levels in patients with SS (p= 0.046). No significant relationship was found between IL-37 levels and other clinical and laboratory parameters. Conclusion: Unlike in patients with autoimmune disorders, serum IL-37 levels were found to be lower in patients with SS than in the control subjects, and IL-37 demonstrated a negative correlation with C3 levels.

Anahtar Kelimeler

Kaynakça

1. Cutolo M, Soldano S, Smith V.Pathophysiology of systemic sclerosis: current understanding and new insights. Expert Rev ClinImmunol. 2019;15(7):753-64.
2. Koca SS, Ozgen M, Isik A. Sistemik skleroz etiyopatogenezi. RAED Dergisi.2012;4:39-46.
3. Asano Y. Systemic sclerosis J Dermatol. 2018;45(2):128-38.
4. Denton CP, Khanna D.Systemic sclerosis. Lancet. 2017;390(10103):1685-99.

Ayrıntılar

Birincil Dil

Türkçe

Konular

Sağlık Kurumları Yönetimi

Bölüm

Araştırma Makalesi

Yazarlar

Turgut Bozan ^* Bu kişi benim
Türkiye

Remzi Cevik Bu kişi benim
Türkiye

İbrahim Batmaz Bu kişi benim
Türkiye

İbrahim Gündüz Bu kişi benim
Türkiye

Abdullah Zübeyir Dagli Bu kişi benim
Türkiye

Yayımlanma Tarihi

19 Mart 2023

Gönderilme Tarihi

12 Ekim 2022

Kabul Tarihi

28 Şubat 2023

Yayımlandığı Sayı

Yıl 2023 Cilt: 50 Sayı: 1

DOI

https://doi.org/10.5798/dicletip.1266709

IZ

https://izlik.org/JA82UZ55DT

Kaynak Göster

RIS / Bibtex

APA

Bozan, T., Cevik, R., Batmaz, İ., Gündüz, İ., & Dagli, A. Z. (2023). Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings. Dicle Medical Journal, 50(1), 37-43. https://doi.org/10.5798/dicletip.1266709

AMA

1.Bozan T, Cevik R, Batmaz İ, Gündüz İ, Dagli AZ. Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings. diclemedj. 2023;50(1):37-43. doi:10.5798/dicletip.1266709

Chicago

Bozan, Turgut, Remzi Cevik, İbrahim Batmaz, İbrahim Gündüz, ve Abdullah Zübeyir Dagli. 2023. “Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings”. Dicle Medical Journal 50 (1): 37-43. https://doi.org/10.5798/dicletip.1266709.

EndNote

Bozan T, Cevik R, Batmaz İ, Gündüz İ, Dagli AZ (01 Mart 2023) Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings. Dicle Medical Journal 50 1 37–43.

IEEE

[1]T. Bozan, R. Cevik, İ. Batmaz, İ. Gündüz, ve A. Z. Dagli, “Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings”, diclemedj, c. 50, sy 1, ss. 37–43, Mar. 2023, doi: 10.5798/dicletip.1266709.

ISNAD

Bozan, Turgut - Cevik, Remzi - Batmaz, İbrahim - Gündüz, İbrahim - Dagli, Abdullah Zübeyir. “Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings”. Dicle Medical Journal 50/1 (01 Mart 2023): 37-43. https://doi.org/10.5798/dicletip.1266709.

JAMA

1.Bozan T, Cevik R, Batmaz İ, Gündüz İ, Dagli AZ. Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings. diclemedj. 2023;50:37–43.

MLA

Bozan, Turgut, vd. “Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings”. Dicle Medical Journal, c. 50, sy 1, Mart 2023, ss. 37-43, doi:10.5798/dicletip.1266709.

Vancouver

1.Turgut Bozan, Remzi Cevik, İbrahim Batmaz, İbrahim Gündüz, Abdullah Zübeyir Dagli. Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings. diclemedj. 01 Mart 2023;50(1):37-43. doi:10.5798/dicletip.1266709